A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

R.A. Soo, J.-Y. Han, U. Dafni, B.C. Cho, C.M. Yeo, E. Nadal, E. Carcereny, J. de Castro, M.A. Sala, R. Bernabé, L. Coate, M. Provencio Pulla, R. Garcia Campelo, S. Cuffe, S.M.S. Hashemi, M. Früh, B. Massuti, J. Garcia-Sanchez, M. Dómine, M. Majem, J.-M. Sanchez-Torres, C. Britschgi, M. Pless, G. Dimopoulou, H. Roschitzki-Voser, B. Ruepp, R. Rosell, R.A. Stahel, S. Peters, Rolf Stahel, Solange Peters, Ross Soo, Ji-Youn Han, Martin Früh, Mariano Provencio, Linda Coate, Urania Dafni, Anita Hiltbrunner, Barbara Ruepp, Heidi Roschitzki-Voser, Anita Hiltbrunner, Adriana Gasca-Ruchti, Nino Giacomelli, Rosita Kammler, Nesa Marti, Lionel Nobs, Mariana Pardo-Contreras, Rita Pfister, Anne-Christine Piguet, Sabrina Ribeli-Hofmann, Virginia Rodriguez Martinez, Heidi Roschitzki-Voser, Susanne Roux, Barbara Ruepp, Magdalena Sanchez-Hohl, Mirjam Schneider, Robin Schweri, Sandra Troesch, Isabel Zigomo, Urania Dafni, Zoi Tsourti, Panagiota Zygoura, Marie Kassapian, Katerina Vervita, Georgia Dimopoulou, Charitini Andriakopoulou, Maria Fernandez, Eva Pereira, Carolina Simona, Lisa Tucker, Jillian Burnes, Aisling Barrett, Meghan McGrillen, Catherine Berset, Christine Biaggi, Martin Reist, Priska Rentsch, Linda Coate, Sinead Cuffe, Sayed Hashemi, Ernest Nadal, Enric Carcereny, Javier de Castro, Maria Angeles Sala, Bernabé Reyes, Mariano Provencio Pulla, Rosario Garcia Campelo, Bartomeu Massutí, Jose Garcia, Manuel Dómine, Margarita Majem, Jose Miguel Sanchez, Martin Früh, Christian Britschgi, Miklos Pless, Solange Peters, Ross Soo, Chong Ming Yeo, Ji-Youn Han, Byoung Chul Cho

Open source

DOI: 10.1016/j.annonc.2021.11.010
Published: 2022-02
Container: Annals of Oncology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.annonc.2021.11.010,
title = {A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial},
author = {R.A. Soo and J.-Y. Han and U. Dafni and B.C. Cho and C.M. Yeo and E. Nadal and E. Carcereny and J. de Castro and M.A. Sala and R. Bernabé and L. Coate and M. Provencio Pulla and R. Garcia Campelo and S. Cuffe and S.M.S. Hashemi and M. Früh and B. Massuti and J. Garcia-Sanchez and M. Dómine and M. Majem and J.-M. Sanchez-Torres and C. Britschgi and M. Pless and G. Dimopoulou and H. Roschitzki-Voser and B. Ruepp and R. Rosell and R.A. Stahel and S. Peters and Rolf Stahel and Solange Peters and Ross Soo and Ji-Youn Han and Martin Früh and Mariano Provencio and Linda Coate and Urania Dafni and Anita Hiltbrunner and Barbara Ruepp and Heidi Roschitzki-Voser and Anita Hiltbrunner and Adriana Gasca-Ruchti and Nino Giacomelli and Rosita Kammler and Nesa Marti and Lionel Nobs and Mariana Pardo-Contreras and Rita Pfister and Anne-Christine Piguet and Sabrina Ribeli-Hofmann and Virginia Rodriguez Martinez and Heidi Roschitzki-Voser and Susanne Roux and Barbara Ruepp and Magdalena Sanchez-Hohl and Mirjam Schneider and Robin Schweri and Sandra Troesch and Isabel Zigomo and Urania Dafni and Zoi Tsourti and Panagiota Zygoura and Marie Kassapian and Katerina Vervita and Georgia Dimopoulou and Charitini Andriakopoulou and Maria Fernandez and Eva Pereira and Carolina Simona and Lisa Tucker and Jillian Burnes and Aisling Barrett and Meghan McGrillen and Catherine Berset and Christine Biaggi and Martin Reist and Priska Rentsch and Linda Coate and Sinead Cuffe and Sayed Hashemi and Ernest Nadal and Enric Carcereny and Javier de Castro and Maria Angeles Sala and Bernabé Reyes and Mariano Provencio Pulla and Rosario Garcia Campelo and Bartomeu Massutí and Jose Garcia and Manuel Dómine and Margarita Majem and Jose Miguel Sanchez and Martin Früh and Christian Britschgi and Miklos Pless and Solange Peters and Ross Soo and Chong Ming Yeo and Ji-Youn Han and Byoung Chul Cho},
year = {2022},
journal = {Annals of Oncology},
doi = {10.1016/j.annonc.2021.11.010},
url = {https://doi.org/10.1016/j.annonc.2021.11.010}
}

RIS

TY  - JOUR
TI  - A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
AU  - R.A. Soo
AU  - J.-Y. Han
AU  - U. Dafni
AU  - B.C. Cho
AU  - C.M. Yeo
AU  - E. Nadal
AU  - E. Carcereny
AU  - J. de Castro
AU  - M.A. Sala
AU  - R. Bernabé
AU  - L. Coate
AU  - M. Provencio Pulla
AU  - R. Garcia Campelo
AU  - S. Cuffe
AU  - S.M.S. Hashemi
AU  - M. Früh
AU  - B. Massuti
AU  - J. Garcia-Sanchez
AU  - M. Dómine
AU  - M. Majem
AU  - J.-M. Sanchez-Torres
AU  - C. Britschgi
AU  - M. Pless
AU  - G. Dimopoulou
AU  - H. Roschitzki-Voser
AU  - B. Ruepp
AU  - R. Rosell
AU  - R.A. Stahel
AU  - S. Peters
AU  - Rolf Stahel
AU  - Solange Peters
AU  - Ross Soo
AU  - Ji-Youn Han
AU  - Martin Früh
AU  - Mariano Provencio
AU  - Linda Coate
AU  - Urania Dafni
AU  - Anita Hiltbrunner
AU  - Barbara Ruepp
AU  - Heidi Roschitzki-Voser
AU  - Anita Hiltbrunner
AU  - Adriana Gasca-Ruchti
AU  - Nino Giacomelli
AU  - Rosita Kammler
AU  - Nesa Marti
AU  - Lionel Nobs
AU  - Mariana Pardo-Contreras
AU  - Rita Pfister
AU  - Anne-Christine Piguet
AU  - Sabrina Ribeli-Hofmann
AU  - Virginia Rodriguez Martinez
AU  - Heidi Roschitzki-Voser
AU  - Susanne Roux
AU  - Barbara Ruepp
AU  - Magdalena Sanchez-Hohl
AU  - Mirjam Schneider
AU  - Robin Schweri
AU  - Sandra Troesch
AU  - Isabel Zigomo
AU  - Urania Dafni
AU  - Zoi Tsourti
AU  - Panagiota Zygoura
AU  - Marie Kassapian
AU  - Katerina Vervita
AU  - Georgia Dimopoulou
AU  - Charitini Andriakopoulou
AU  - Maria Fernandez
AU  - Eva Pereira
AU  - Carolina Simona
AU  - Lisa Tucker
AU  - Jillian Burnes
AU  - Aisling Barrett
AU  - Meghan McGrillen
AU  - Catherine Berset
AU  - Christine Biaggi
AU  - Martin Reist
AU  - Priska Rentsch
AU  - Linda Coate
AU  - Sinead Cuffe
AU  - Sayed Hashemi
AU  - Ernest Nadal
AU  - Enric Carcereny
AU  - Javier de Castro
AU  - Maria Angeles Sala
AU  - Bernabé Reyes
AU  - Mariano Provencio Pulla
AU  - Rosario Garcia Campelo
AU  - Bartomeu Massutí
AU  - Jose Garcia
AU  - Manuel Dómine
AU  - Margarita Majem
AU  - Jose Miguel Sanchez
AU  - Martin Früh
AU  - Christian Britschgi
AU  - Miklos Pless
AU  - Solange Peters
AU  - Ross Soo
AU  - Chong Ming Yeo
AU  - Ji-Youn Han
AU  - Byoung Chul Cho
PY  - 2022
JO  - Annals of Oncology
DO  - 10.1016/j.annonc.2021.11.010
UR  - https://doi.org/10.1016/j.annonc.2021.11.010
ER  -

APA

Soo, R., Han, J., Dafni, U., Cho, B., Yeo, C., Nadal, E., Carcereny, E., Castro, J. D., Sala, M., Bernabé, R., Coate, L., Pulla, M. P., Campelo, R. G., Cuffe, S., Hashemi, S., Früh, M., Massuti, B., Garcia-Sanchez, J., Dómine, M., Majem, M., Sanchez-Torres, J., Britschgi, C., Pless, M., Dimopoulou, G., Roschitzki-Voser, H., Ruepp, B., Rosell, R., Stahel, R., Peters, S., Stahel, R., Peters, S., Soo, R., Han, J., Früh, M., Provencio, M., Coate, L., Dafni, U., Hiltbrunner, A., Ruepp, B., Roschitzki-Voser, H., Hiltbrunner, A., Gasca-Ruchti, A., Giacomelli, N., Kammler, R., Marti, N., Nobs, L., Pardo-Contreras, M., Pfister, R., Piguet, A., Ribeli-Hofmann, S., Martinez, V. R., Roschitzki-Voser, H., Roux, S., Ruepp, B., Sanchez-Hohl, M., Schneider, M., Schweri, R., Troesch, S., Zigomo, I., Dafni, U., Tsourti, Z., Zygoura, P., Kassapian, M., Vervita, K., Dimopoulou, G., Andriakopoulou, C., Fernandez, M., Pereira, E., Simona, C., Tucker, L., Burnes, J., Barrett, A., McGrillen, M., Berset, C., Biaggi, C., Reist, M., Rentsch, P., Coate, L., Cuffe, S., Hashemi, S., Nadal, E., Carcereny, E., Castro, J. D., Sala, M. A., Reyes, B., Pulla, M. P., Campelo, R. G., Massutí, B., Garcia, J., Dómine, M., Majem, M., Sanchez, J. M., Früh, M., Britschgi, C., Pless, M., Peters, S., Soo, R., Yeo, C. M., Han, J., & Cho, B. C. (2022). A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial. Annals of Oncology. https://doi.org/10.1016/j.annonc.2021.11.010

Source records

crossref · retrieved 2026-09-25T23:48:34.120Z